PROFIL KEAMANAN METFORMIN PADA PASIEN DIABETES MELITUS TIPE DUA DENGAN INFEKSI COVID - 19: TINJAUAN SISTEMATIS
Diabetes Mellitus (DM) type two is a challenge for the management of COVID-19. Metformin is the treatment of choice for DM type two patients with COVID-19. At this time, there are no studies related to how the safety aspects of these drugs are used in DM type two patients with COVID-19. This study a...
সংরক্ষণ করুন:
| প্রধান লেখক: | |
|---|---|
| বিন্যাস: | গ্রন্থ |
| প্রকাশিত: |
2021-07-27.
|
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | Link Metadata |
| ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | repoupnvj_11602 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Veriantara Satya Dhika, . |e author |
| 245 | 0 | 0 | |a PROFIL KEAMANAN METFORMIN PADA PASIEN DIABETES MELITUS TIPE DUA DENGAN INFEKSI COVID - 19: TINJAUAN SISTEMATIS |
| 260 | |c 2021-07-27. | ||
| 500 | |a http://repository.upnvj.ac.id/11602/1/ABSTRAK.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/11602/27/AWAL.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/11602/3/BAB%201.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/11602/4/BAB%202.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/11602/5/BAB%203.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/11602/6/BAB%204.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/11602/7/BAB%205.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/11602/28/DAFTAR%20PUSTAKA.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/11602/29/RIWAYAT%20HIDUP.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/11602/25/LAMPIRAN.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/11602/11/ARTIKEL%20KI.pdf | ||
| 520 | |a Diabetes Mellitus (DM) type two is a challenge for the management of COVID-19. Metformin is the treatment of choice for DM type two patients with COVID-19. At this time, there are no studies related to how the safety aspects of these drugs are used in DM type two patients with COVID-19. This study aims to determine the safety profile of metformin in DM type two patients with COVID-19. The method used is systematic with a combination of data from several different database articles, namely PubMed, Medline (Ovid), ScienceDirect, Cochrane Library, ClinicalTrials. gov, and medrxiv.org. A total of 23 study articles from 2020-2021 meet the inclusion criteria and are of very good quality. The results of this study indicate a sufficient safety profile in terms of mortality, good life, hospital and ICU admissions, several comorbidities, risk of complications, diagnosis and severity. Based on its safety profile, metformin remains a definite use for type 2 DM patients with COVID-19 infection. | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 690 | |a RC Internal medicine | ||
| 655 | 7 | |a Thesis |2 local | |
| 655 | 7 | |a NonPeerReviewed |2 local | |
| 787 | 0 | |n http://repository.upnvj.ac.id/11602/ | |
| 787 | 0 | |n http://repository.upnvj.ac.id | |
| 856 | 4 | 1 | |u http://repository.upnvj.ac.id/11602/ |z Link Metadata |